Yuandan Wei

Yuandan Wei

Auto-generated profile, based on publicly available information

Yuandan Wei

School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
YGYuqin Gu
Yuqin Gu
HZHao Zheng
Hao Zheng
PWPiao Wang
Piao Wang
YLYanhong Liu
Yanhong Liu
XGXinxin Guo
Xinxin Guo
SLSiyang Liu
Siyang Liu
Gestational diabetes mellitus, a heritable metabolic disorder and the most common pregnancy-related condition, remains understudied regarding its genetic architecture and its potential for early prediction using genetic data. Here we conducted genome-wide association studies on 116,144 Chinese pregnancies, leveraging their non-invasive prenatal test sequencing data and detailed prenatal records. We identified 13 novel loci for gestational diabetes mellitus and 111 for five glycemic traits, with minor allele frequencies of 0.01-0.5 and absolute effect sizes of 0.03-0.62. Approximately 50% of these loci were specific to gestational diabetes mellitus and gestational glycemic levels, distinct from type 2 diabetes and general glycemic levels in East Asians. A machine learning model integrating polygenic risk scores and prenatal records predicted gestational diabetes mellitus before 20 weeks of gestation, achieving an area under the receiver operating characteristic curve of 0.729 and an accuracy of 0.835. Shapley values highlighted polygenic risk scores as key contributors. This model offers a cost-effective strategy for early gestational diabetes mellitus prediction using clinical non-invasive prenatal test.

11 April 2024 in Blood
Verified
Journal Article
Open access
PDF file
ZYZijing Yang
Zijing Yang
LHLiang Hu
Liang Hu
JZJianxin Zhen
Jianxin Zhen
YGYuqin Gu
Yuqin Gu
YLYanhong Liu
Yanhong Liu
SLSiyang Liu
Siyang Liu
Platelet count reduction occurs throughout pregnancy, with 5% to 12% of pregnant women being diagnosed with gestational thrombocytopenia (GT), characterized by a more marked decrease in platelet count during pregnancy. However, the underlying biological mechanism behind these phenomena remains unclear. Here, we used sequencing data from noninvasive prenatal testing of 100 186 Chinese pregnant individuals and conducted, to our knowledge, the hitherto largest-scale genome-wide association studies on platelet counts during 5 periods of pregnancy (the first, second, and third trimesters, delivery, and the postpartum period) as well as 2 GT statuses (GT platelet count < 150 × 109/L and severe GT platelet count < 100 × 109/L). Our analysis revealed 138 genome-wide significant loci, explaining 10.4% to 12.1% of the observed variation. Interestingly, we identified previously unknown changes in genetic effects on platelet counts during pregnancy for variants present in PEAR1 and CBL, with PEAR1 variants specifically associated with a faster decline in platelet counts. Furthermore, we found that variants present in PEAR1 and TUBB1 increased susceptibility to GT and severe GT. Our study provides insight into the genetic basis of platelet counts and GT in pregnancy, highlighting the critical role of PEAR1 in decreasing platelet counts during pregnancy and the occurrence of GT. Those with pregnancies carrying specific variants associated with declining platelet counts may experience a more pronounced decrease, thereby elevating the risk of GT. These findings lay the groundwork for further investigation into the biological mechanisms and causal implications of GT.

13 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YWYuandan Wei
Yuandan Wei
JZJianxin Zhen
Jianxin Zhen
LHLiang Hu
Liang Hu
YGYuqin Gu
Yuqin Gu
YLYanhong Liu
Yanhong Liu
SLSiyang Liu
Siyang Liu
Maintaining normal thyroid function is crucial in pregnancy, yet thyroid dysfunction and the presence of thyroid peroxidase antibodies (TPOAb) affect 0.5% to 18% of pregnant women. Here, we conducted a genome-wide association study (GWAS) of eight thyroid traits, including two thyroid-related hormones, four thyroid dysfunctions, and two thyroid autoimmunity measurements among 85,421 Chinese pregnant women to investigate the genetic basis of thyroid function during pregnancy. Our study identified 176 genetic loci, including 125 previously unknown genome-wide associations. Joint epidemiological and Mendelian randomization analyses revealed significant associations between the gestational thyroid phenotypes and gestational complications, birth outcomes, and later-age health outcomes. Specifically, genetically elevated thyroid-stimulating hormone (TSH) levels during pregnancy correlated with lower glycemic levels, reduced blood pressure, and longer gestational duration. Additionally, TPOAb and thyroid functions during pregnancy share genetic correlations with later-age thyroid and cardiac disorders. These findings provide insights into the genetic determinants of thyroid traits during pregnancy, which may lead to new therapeutics, early pre-diagnosis and preventive strategies starting from early adulthood.

14 November 2024 in Journal of Hepatology
Verified
Journal Article
Open access
YLYanhong Liu
Yanhong Liu
YWYuandan Wei
Yuandan Wei
XCXiaohang Chen
Xiaohang Chen
SHShujia Huang
Shujia Huang
YGYuqin Gu
Yuqin Gu
SLSiyang Liu
Siyang Liu
Intrahepatic cholestasis of pregnancy (ICP) is the most common and high-risk liver disorder during pregnancy, with varying prevalence across populations. Our understanding of the mechanisms underlying ICP and population-level differences remains limited. This study delves into the genetic etiology of ICP in East Asians, drawing comparisons with Europeans to comprehend ICP etiology in the context of genetic background and evolution. We conducted the hitherto largest-scale genome-wide association study on fasting total serum bile acids (TBA) and ICP in 98,269 Chinese pregnancies. The findings were replicated in three cohorts and compared with European populations. Additionally, phenome-wide association and spatio-temporal evolution analyses were employed to investigate the function and evolutionary patterns of ICP-associated loci. We identified eight loci for fasting TBA and four for ICP, including ten novel loci. Notably, we discovered an East Asian-specific locus within a 0.4 Mbp region at 14q24.1, which increases fasting TBA by 6.12 μmol/L and ICP risk by 16.56-fold per risk allele (95% CI 16.43 to 16.69, p = 7.06×10-381). Phenome-wide association and spatial-temporal evolution analyses revealed that this 14q24.1 ICP risk locus confers resistance to hepatitis B and has become prevalent in East and Southeast Asia within the last 3,000 years. We uncovered a distinct genetic etiology of ICP in East Asians, likely linked to a historic HBV epidemic in East and Southeast Asia within the last 3,000 years. These findings enhance our understanding of ICP pathophysiology and offer potential for more precise detection, assessment, and treatment of the disorder. This study provides novel insights into the genetic basis of intrahepatic cholestasis of pregnancy (ICP) in East Asian populations, where little was previously known. The identification of the East-Asian-specific 14q24.1 locus, associated with both fasting total serum bile acids and ICP, and its connection to a historical hepatitis B epidemic emphasize the importance of incorporating population-specific history into disease research. These findings are crucial for researchers studying pregnancy-related liver disorders and clinicians providing care to pregnant women, enabling more accurate screening, risk assessment, and targeted interventions for ICP.

9 December 2025 in eClinicalMedicine
Verified
Journal Article
Open access
SCShiyao Cheng
Shiyao Cheng
YWYuandan Wei
Yuandan Wei
HZHuaguang Zheng
Huaguang Zheng
QZQingrong Zhang
Qingrong Zhang
XYXuanyan Yang
Xuanyan Yang
SLSiyang Liu
Siyang Liu
Stroke is a leading cause of mortality and disability globally, with high rates of adverse outcomes. We aimed to develop and test a clinically accessible and explainable predictive model for post-stroke composite outcomes that could identify patients at high-risk for targeted interventions. This modelling study used artificial intelligence to develop and validate a prognostic predictive model for post-stroke outcomes at 3 months and over 5 years, using comprehensive data from the third China National Stroke Registry (CNSR-III; 2015–2018). The development cohort comprised 11,313 patients from CNSR-III. Validation cohort 1 (n = 2627 from CNSR-III; internal validation) were selected at random on the basis of hospital assignment. Validation cohort 2 (external validation) included 5158 patients with a history of ischaemic stroke, excluding those diagnosed with TIA, from the CHANCE-2 trial (2019–2021) done at 202 centres in China. Validation cohort 3 (external validation: disability and mortality) involved 3855 patients with a history of acute ischaemic stroke or TIA from a single centre in the Clinical Research Center for Stroke–Fifth Division (CRCS-5) cohort (2011–2024) in South Korea. We evaluated 309 hospitalisation variables, including baseline characteristics, medical history, hospitalisation data, biomarkers, geographical factors, National Institutes of Health Stroke Scale (NIHSS) scores, modified Rankin Scale (mRS), and stroke polygenic risk scores, using an extreme gradient boosting tree model. Feature importance was assessed via Shapley values. Primary outcomes were 3-month stroke recurrence, disability (mRS >2), and mortality. Secondary outcomes were assessed at six additional time points over 5 years. A nested cross-validation scheme was employed for feature selection and internal validation in 80% of patients (n = 11,313) from CNSR-III cohort. Testing was performed in the remaining 20% of patients (n = 2627) from CNSR-III (validation cohort 1). External validation was performed in validation cohorts 2 and 3. Global and domain-specific delta-NIHSS(admission-discharge) emerged as the strongest predictor of stroke recurrence, disability, and mortality. The Delta-NIHSS-based Predictor for Post-Stroke Composite Outcomes (DISCO) model, integrating 16 delta-NIHSS(admission-to-discharge) measures, age, gender, TOAST subtypes, history of TIA, stroke, diabetes and mRS at discharge, achieved the area under the receiver operating curve (AUCs) of 0.805 and 0.815 for recurrence and mortality and of 0.852 for disability at 3 months in validation cohort 2. The 1% patients with highest-risk exhibited a 19.27-fold relative risk (RR) for recurrence, 36.59-fold RR for disability, and 225.5-fold RR for mortality at 3 months. The DISCO model is available at https://www.discosysu.cn. The DISCO model, incorporating 23 clinical variables, demonstrates high accuracy, robustness, clinical accessibility, and explainability in predicting post-stroke outcomes. The predictive strength of delta-NIHSS(admission-discharge) provides mechanistic insights into stroke outcomes and could potentially inform future acute stroke treatment and rehabilitation strategies. Future studies, with external validation across diverse ancestries and mechanistic studies elucidating the predictive power of delta-NIHSS in stroke recovery, are warranted. 10.13039/501100012166 National Key Research and Development Program of China, 10.13039/501100001809 National Natural Science Foundation of China , Young Elite Scientists Sponsorship Program by the China Association for Science and Technology, and Young Talents Supporting Program of Capital Medical University.

31 January 2024 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
PDF file
SCShiyao Cheng
Shiyao Cheng
HZHao Zheng
Hao Zheng
YWYuandan Wei
Yuandan Wei
XLXingchen Lin
Xingchen Lin
YGYuqin Gu
Yuqin Gu
SLSiyang Liu
Siyang Liu
Background and aims: Observational studies have implicated the involvement of gut microbiome in stroke development. Conversely, stroke may disrupt the gut microbiome balance, potentially causing systemic infections exacerbated brain infarction. However, the causal relationship remains controversial or unknown. To investigate bidirectional causality and potential ethnic differences, we conducted a bidirectional two-sample Mendelian randomisation (MR) study in both East Asian (EAS) and European (EU) populations. Methods: Leveraging the hitherto largest genome-wide association study (GWAS) summary data from the MiBioGen Consortium (n=18 340, EU) and BGI (n=2524, EAS) for the gut microbiome, stroke GWAS data from the GIGASTROKE Consortium(264 655 EAS and 1 308 460 EU), we conducted bidirectional MR and sensitivity analyses separately for the EAS and EU population. Results: We identified nominally significant associations between 85 gut microbiomes taxa in EAS and 64 gut microbiomes taxa in EU with stroke or its subtypes. Following multiple testing, we observed that genetically determined 1 SD increase in the relative abundance of species Bacteroides pectinophilus decreased the risk of cardioembolic stroke onset by 28% (OR 0.72 (95% CI 0.62 to 0.84); p=4.22e−5), and that genetically determined 1 SD increase in class Negativicutes resulted in a 0.76% risk increase in small vessel stroke in EAS. No significant causal association was identified in the EU population and the reverse MR analysis. Conclusion: Our study revealed subtype-specific and population-specific causal associations between gut microbiome and stroke risk among EAS and EU populations. The identified causality holds promise for developing a new stroke prevention strategy, warrants further mechanistic validation and necessitates clinical trial studies.